Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29622466 | 0.89 | NAMPT (0.43) | NAMPTSOS1SOS2 | |
| SCHEMBL1771082 | 0.89 | NAMPT (0.43) | NAMPTSOS1SOS2 | |
| SCHEMBL15758654 | 0.88 | CYP1A2 (0.33) | NAMPT | |
| SCHEMBL20744448 | 0.87 | SOS1 (0.43) | NAMPTSOS1SOS2 | |
| SCHEMBL18706072 | 0.86 | SOS1 (0.39) | NAMPTSOS1SOS2 | |
| SCHEMBL21591724 | 0.85 | PARP1 (0.30) | — | |
| SCHEMBL1078904 | 0.82 | SOS1 (0.50) | NAMPTSOS1SOS2 | |
| SCHEMBL29711975 | 0.82 | NAMPT (0.34) | NAMPTSOS1SOS2 | |
| SCHEMBL12910558 | 0.81 | SOS1 (0.40) | NAMPTSOS1SOS2 | |
| SCHEMBL18132140 | 0.79 | SOS1 (0.43) | NAMPTSOS1SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119032096-A | Heterocyclic compounds and their use | 金橘生物科技公司 | 2024-11-26 | — | — | CN | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022117075-A1 | AZACYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 广州费米子科技有限责任公司 | 2022-06-09 | — | — | WO | disclosed |
| EP-3426664-B1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-10898504-B2 | Substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-26 | — | — | US | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | NAMPT 2275/4885SOS1 94/4885SOS2 176/4885 |
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | NAMPT 172/4885SOS1 4635/4885SOS2 4790/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NAMPT 2275/4885SOS1 94/4885SOS2 176/4885 |
| US-10898504-B2 | Substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | NAMPT 145/4885SOS1 4524/4885SOS2 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.